In subgroup analysis, we found that FPG, HDL-c, ALT, and DBP could serve as the potential effect modifiers to modify the relationship between eGFR and NAFLD risk. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.